Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Zonisamide
Drug ID BADD_D02396
Description Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may be a carbonic anhydrase inhibitor although this is not one of the primary mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.
Indications and Usage For use as adjunctive treatment of partial seizures in adults with epilepsy.
Marketing Status approved; investigational
ATC Code N03AX15
DrugBank ID DB00909
KEGG ID D00538
MeSH ID D000078305
PubChem ID 5734
TTD Drug ID D09ZIS
NDC Product Code 76282-228; 13672-001; 60510-611; 65841-125; 70600-003; 59651-380; 63629-3293; 68001-242; 68462-129; 70771-1143; 72578-040; 76282-226; 38217-0040; 59651-378; 35356-143; 59212-681; 63187-897; 70518-3224; 70771-1144; 49452-9000; 76072-1012; 0615-8266; 72578-041; 60687-230; 61919-917; 62756-259; 62756-260; 17511-137; 68554-0009; 29300-430; 63187-583; 69097-861; 71335-0486; 71052-065; 52652-8001; 68001-244; 76282-227; 13672-002; 51927-0109; 51927-4807; 59361-002; 59212-680; 59651-379; 46438-0063; 60510-610; 66039-122; 73309-257; 29300-429; 62756-258; 70771-1142; 51552-1572; 73377-112; 68001-243; 68788-7438; 72578-042; 62756-334; 29300-428; 50268-816; 68462-128; 68462-130; 70518-3180; 71205-727; 71335-0962; 71335-9679; 72189-374; 38779-3045; 66039-929
UNII 459384H98V
Synonyms Zonisamide | 3-Sulfamoylmethyl-1,2-benzisoxazole | 3 Sulfamoylmethyl 1,2 benzisoxazole | AD 810 | AD-810 | AD810 | CI 912 | CI-912 | CI912 | Zonegran | Zonisamide Monosodium
Chemical Information
Molecular Formula C8H8N2O3S
CAS Registry Number 68291-97-4
SMILES C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Panic attack19.06.04.0010.000622%Not Available
Paraesthesia17.02.06.005; 23.03.03.094--
Paranoia19.05.01.0050.000829%Not Available
Parosmia22.04.03.007; 17.04.04.002--Not Available
Peptic ulcer07.04.07.001--Not Available
Personality change17.02.05.019; 19.05.01.0060.000622%
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Photophobia06.01.01.004; 17.17.02.006--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pneumonia aspiration22.07.01.015; 11.01.09.019--Not Available
Pollakiuria20.02.02.0070.000912%
Polyuria20.02.03.0020.000622%Not Available
Posture abnormal15.03.05.029; 17.02.05.0330.000414%Not Available
Pruritus23.03.12.001--
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.000414%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.0040.000622%
Rash pustular23.03.10.003; 11.01.12.002--
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Renal colic20.02.03.0100.000414%
Renal failure20.01.03.005--Not Available
Renal tubular acidosis14.01.01.005; 20.05.03.003--Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.001450%
Restlessness19.11.02.002; 17.02.05.0210.001119%
Rhabdomyolysis15.05.05.002--
Rhinitis22.07.03.006; 11.01.13.004--
Road traffic accident12.01.08.006--Not Available
Schizophreniform disorder19.03.02.001--Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 12 Pages